Showing results (301-310 of 427) with videos related to

Sort By:
Pageof 43
The Lancet. Oncology|September 26, 2015
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort studyFabio Efficace, Gianluca Gaidano, Massimo Breccia, et al.
Leukemia & Lymphoma|February 26, 2013
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacyEsther N Oliva, Roberto Latagliata, Carmelo Laganà, et al.
Annals of Hematology|April 20, 2016
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter studyFrancesco Buccisano, Anna Lina Piccioni, Carolina Nobile, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 13, 2013
International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24Fabio Efficace, Michele Baccarani, Massimo Breccia, et al.
Oncology Research and Treatment|October 9, 2019
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with ImatinibLaura Cesini, Ida Carmosino, Massimo Breccia, et al.
Leukemia|February 23, 2020
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS indexFabio Efficace, Francesco Cottone, Laura B Oswald, et al.
Leukemia & Lymphoma|September 2, 2020
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significanceSara Mohamed, Roberto Latagliata, Maria Zaira Limongi, et al.
Leukemia|September 4, 2019
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapyFabio Efficace, Fabio Stagno, Alessandra Iurlo, et al.
Blood|October 14, 2009
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaGianantonio Rosti, Francesca Palandri, Fausto Castagnetti, et al.
Leukemia|April 9, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final resultsJorge E Cortes, Fabian Lang, Delphine Rea, et al.
Pageof 43